- Hyperbaric Oxygen Therapy (HBOT), a treatment that involves breathing pure oxygen in a pressurized room or chamber, is gaining traction across the U.S. due to its wide applicability in treating conditions such as diabetic foot ulcers, carbon monoxide poisoning, radiation injuries, and non-healing wounds
- The rising prevalence of chronic diseases, particularly diabetes and vascular disorders, is a significant driver for HBOT demand, alongside increasing adoption in wound care centers, rehabilitation clinics, and hospitals
- The Monoplace segment dominated the U.S. hyperbaric oxygen therapy (HBOT) market with the largest revenue share of 57.6% in 2024, owing to its widespread usage in hospitals and outpatient clinics due to lower operational requirements, patient comfort, and affordability
